These are research hypotheses or model-specific observations, not established clinical mechanisms
The reduction of cardiovascular events is not only related to anti-diabetic properties, but also to pleotropic effects leading to the reduction of the residual cardiovascular risk, that has been defined as the risk of progression of CV events (MACE or HF) that remains after the optimal glycaemic control in T2DM patients, and it seems to be related to meta-inflammation, defined as a low-grade chronic and sterile inflammatory status
If you are just beginning, that means month one at the starting dose
33, 833844.e5
This does not mean you can never enjoy dessert again
Kardie Tobb, DO, MS, FASPC, FACC, a boardcertified preventive cardiologist and the medical director for the Cone Health HeartCare Women's Heart Health and Cardio-Obstetrics Clinic, explains some of the most common reasons why GLP-1s may not deliver the results you're hoping for, including: You need a higher dose and have not yet reached a therapeutic dose as determined by your doctor High intake of liquid calories , including alcohol and ultra-processed foods Not getting enough protein , which can leave you persistently hungry and makes it harder to feel full Advanced diabetes or insulin resistance Taking other medications such as sulfonylureas, which lower blood sugar but can lead to weight gain Not adhering to your dosing schedule , such as inconsistent weekly injections or missed doses Differences in gut hormones or genetics And just because your GLP-1 isn't working immediately doesn't mean it won't work for you